The brain targeting efficiency following nasally applied MPEG-PLA nanoparticles in rats

References

• Almeida AJ, Alpar HO, Brown MRW. Immune response to nasal delivery of antigenically intact tetanus toxoid associated with poly(l-lactic acid) microspheres in rats, rabbits and Guineapigs. J Pharm Pharmacol 1993; 45: 198–203
   PubMed Web of Science ®Google Scholar
• de Ascentiis A, de Grazia JL, Bowman CN, Colombo P, Peppas NA. Mucoadhesion of poly(2-hydroxyethyl methacrylate) is improved when linear poly(ethylene oxide) chains are added to the polymer network. J Control Release 1995; 33: 197–201
   Web of Science ®Google Scholar
• Banks WA, During MJ, Niehoff ML. Brain uptake of the glucagon-like peptide-1 antagonist exendin (9–39) after intranasal administration. J Pharmacol Exp Ther 2004; 309: 469–475
   PubMed Web of Science ®Google Scholar
• Blardi P, Urso R, De Lalla A, Volpi L, Perri TD, Auteri A. Nimodipine: Drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. Clin Pharmacol Ther 2002; 72: 556–561
   PubMed Web of Science ®Google Scholar
• Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL. Sniffing neuropeptides: A transnasal approach to the human brain. Nature Neurosci 2002; 5: 514–516
   PubMed Web of Science ®Google Scholar
• Brooking J, Davis SS, Illum L. Transport of nanoparticles across the rat nasal mucosa. J Drug Target 2001; 9: 267–279
   PubMed Web of Science ®Google Scholar
• Chou KJ, Donovan MD. The distribution of local anaesthetics into the CSF following intranasal administration. Int J Pharm 1998; 168: 137–145
   Web of Science ®Google Scholar
• Chow HHS, Chen Z, Matsuura GT. Direct transport of cocaine from the nasal cavity to the brain following intranasal cocaine administration in rats. J Pharm Sci 1999; 88: 754–758
   PubMed Web of Science ®Google Scholar
• Dahlin M, Björk E. Nasal absorption of (S)-UH-301 and its transport into the cerebrospinal fluid of rats. Int J Pharm 2000; 195: 197–205
   PubMed Web of Science ®Google Scholar
• Desai MP, Labhasetwar V, Walter E, Levy RJ, Amidon GL. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm Res 1997; 14: 1568–1573
   PubMed Web of Science ®Google Scholar
• Dufes C, Olivier JC, Gaillard F, Gaillard A, Couet W, Muller JM. Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats. Int J Pharm 2003; 255: 87–97
   PubMed Web of Science ®Google Scholar
• Erdlenbruch B, Alipour M, Fricker G, Miller DS, Kugler W, Eibl H, Lakomek M. Alkylglycerol opening of the blood–brain barrier to small and large fluorescence markers in normal and C6 glioma-bearing rats and isolated rat brain capillaries. Br J Pharmacol 2003; 140: 1201–1210
   PubMed Web of Science ®Google Scholar
• Fernandez-Urrusuno R, Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso M. Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm Res 1999; 16: 1576–1581
   PubMed Web of Science ®Google Scholar
• Frey WH, II, Liu J, Chen X, Thorne RG, Fawcett RG, Ala TA, Rahman YE. Delivery of 125I-NGF to the brain via the olfactory route. Drug Deliv 1997; 4: 87–92
   Web of Science ®Google Scholar
• Frey WH, II. Intranasal delivery: Bypassing the blood–brain barrier to deliver therapeutic agents to the brain and spinal cord. Drug Deliv Technol 2002; 2: 46–49
   Google Scholar
• Gizurarson S, Thorvaldsson T, Sigurdsson P, Gunnarsson E. Selective delivery of insulin into the brain: Intraolfactory absorption. Int J Pharm 1996; 140: 77–83
   Web of Science ®Google Scholar
• Graff CL, Pollack GM. Nasal drug administration: Potential for targeted central nervous system delivery. J Pharm Sci 2005; 94: 1187–1195
   PubMed Web of Science ®Google Scholar
• Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 2000; 11: 1–18
   PubMed Web of Science ®Google Scholar
• Illum L. Nasal drug delivery-possibilities, problems and solutions. J Control Release 2003; 87: 187–198
   PubMed Web of Science ®Google Scholar
• Janes KA, Calvo P, Alonso MJ. Polysaccharide colloidal particles as delivery systems for macromolecules. Adv Drug Deliv Rev 2001; 47: 83–97
   PubMed Web of Science ®Google Scholar
• Jani PU, Halbert GW, Langridge J, Florence AT. The uptake and translocation of latex nanospheres and microspheres after oral administration to rats. J Pharm Pharmacol 1989; 41: 809–812
   PubMed Web of Science ®Google Scholar
• Johnson MD, Chen J, Anderson BD. Investigation of the mechanism of enhancement of central nervous system delivery of 2′-beta-fluoro-2′,3′-dideoxyinosine via a blood–brain barrier adenosine deaminase-activated prodrug. Drug Metab Dispos 2002; 30: 191–198
   PubMed Web of Science ®Google Scholar
• Lindhardt K, Ravn C, Gizurarson S, Bechgaard E. Intranasal absorption of buprenorphine-in vivo bioavailability study in sheep. Int J Pharm 2000; 205: 159–163
   PubMed Web of Science ®Google Scholar
• Lu W, Zhang Y, Tan YZ, Hu KL, Jiang XG, Fu SK. Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery. J Control Release 2005; 107: 428–448
   PubMed Web of Science ®Google Scholar
• Mathison S, Nagilla R, Kompella UB. Nasal route for direct delivery of solutes to the central nervous system: Fact or fiction?. J Drug Target 1998; 5: 415–441
   PubMed Web of Science ®Google Scholar
• Muck W, Bode H. Bioanalytics of nimodipine—an overview of methods. Pharmazie 1994; 49: 130–139
   PubMed Web of Science ®Google Scholar
• Muck W, Breuel HP, Kuhlmann J. The influence of age on the pharmacokinetics of nimodipine. Int J Clin Pharmacol 1996; 34: 293–298
   Google Scholar
• Pantoni L, Rossi R, Inzitari D, Bianchi C, Beneke M, Erkinjuntti T, Wallin T. Efficacy and safety of nimodipine in subcortical vascular dementia: A subgroup analysis of the scandinavian multi-infarct dementia trial. J Neurol Sci 2000; 175: 124–134
   PubMed Web of Science ®Google Scholar
• Pardridge WM. CNS drug design based on principles of blood–brain barrier transport. J Neurochem 1998; 70: 1781–1792
   PubMed Web of Science ®Google Scholar
• Peppas NA. Molecular calculations of poly(ethylene glycol) transport across a swollen poly(agrylic acid)/mucin interface. J Biomater Sci Polymer Edn 1998; 9: 535–542
   PubMed Web of Science ®Google Scholar
• Plard JP, Bazile D. Comparison of the safety profiles of PLA50 and Me*PEG-PLA50 nanoparticles after single dose intravenous administration to rat. Colloids Surf B Biointerf 1999; 16: 173–183
   Web of Science ®Google Scholar
• Rameis H. Principles of the pharmacokinetics and pharmacodynamics of calcium anatagonists. Wien Med Wochenschr 1993; 143: 490–500
   PubMedGoogle Scholar
• Ross TM, Martinez PM, Renner JC, Thorne RG, Hanson LR, Frey WH, II. Intrranasal administration of interferon beta bypasses the blood–brain barrier to target the central nervous system and cervical lymph nodes: A non-invasive treatment strategy for multiple sclerosis. J Neurochem 2004; 151: 66–77
   Google Scholar
• Tobío M, Gref R, Sánchez A, Langer R, Alonso MJ. Stealth PLA-PEG nanoparticles as protein carriers for nasal administration. Pharm Res 1998; 15: 270–275
   PubMed Web of Science ®Google Scholar
• Vila A, Sánchez A, Pérez C, Alonso MJ. PLA-PEG nanospheres: New carriers for transmucosal delivery of proteins and plasmid DNA. Polym Adv Technol 2002a; 13: 1–8
   Web of Science ®Google Scholar
• Vila A, Sánchez A, Tobio M, Calvo P, Alonso MJ. Design of biodegradable particles for protein delivery. J Control Release 2002b; 78: 15–24
   PubMed Web of Science ®Google Scholar
• Vila A, Gill H, McCallion O, Alonso MJ. Transport of PLA-PEG particles across the nasal mucosa: Effect of particle size and PEG coating density. J Control Release 2004; 98: 231–244
   PubMed Web of Science ®Google Scholar
• Vila A, Sánchez A, Évora C, Soriano I, McCallion O, Alonso MJ. PLA-PEG particles as nasal protein carriers: The influence of the particle size. Int J Pharm 2005; 292: 43–52
   PubMed Web of Science ®Google Scholar
• Wang F, Jiang X, Lu W. Profiles of methotrexate in blood and CSF following intranasal and intravenous administration to rats. Int J Pharm 2003; 263: 1–7
   PubMed Web of Science ®Google Scholar
• Westin U, Piras E, Jansson B, Bergström U, Dahlin M, Brittebo E, Björk E. Transfer of morphine along the olfactory pathway to the central nervous system after nasal administration to rodents. Eur J Pharm Sci 2005; 24: 565–573
   PubMed Web of Science ®Google Scholar
• Yuan J. Estimation of variance for AUC in animal studies. J Pharm Sci 1993; 82: 761–763
   PubMed Web of Science ®Google Scholar
• Zhang JT. Altered calcium homeostasis in brain aging and senile dementia, new approach to treat Alzheimer's disease. Acta Pharm Sin 1993; 28: 641–646
   Google Scholar
• Zhang QZ, Jiang XG, Wu CH. Distribution of nimodipine into brain following intranasal administration in rats. Acta Pharmacol Sin 2004a; 25: 522–527
   PubMed Web of Science ®Google Scholar
• Zhang QZ, Jiang XG, Jiang WM, Lu W, Su LN, Shi ZQ. Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain. Int J Pharm 2004b; 275: 85–96
   PubMed Web of Science ®Google Scholar
• Zhang QZ, Jiang XG, Shi ZQ, Gao KP. The effects of nimodipine on cerebral hemodynamics following intranasal administration in dogs. Acta Pharm Sin 2005; 40: 466–469
   Google Scholar
• Zhang Y, Zhang QZ, Zha LS, Yang WL, Wang CC, Jiang XG, Fu SK. Preparation, characterization and application of pyrene-labelled methoxy poly(ethylene glycol)-poly(lactic acid) copolymer nanoparticles. Colloid Polymer Sci 2004; 282: 1323–1328
   Web of Science ®Google Scholar